

**Government response to the House of Lords Select Committee on Science and Technology report : resistance to antibiotics / presented to Parliament by the Secretary of State for Health by Command of Her Majesty, July 2001.**

**Contributors**

Great Britain. Department of Health.

**Publication/Creation**

Norwich : Stationery Office, 2001.

**Persistent URL**

<https://wellcomecollection.org/works/kcexzxgy>

**wellcome  
collection**


Wellcome Collection  
183 Euston Road  
London NW1 2BE UK  
T +44 (0)20 7611 8722  
E [library@wellcomecollection.org](mailto:library@wellcomecollection.org)  
<https://wellcomecollection.org>



DEPARTMENT OF HEALTH

**GOVERNMENT RESPONSE  
TO THE HOUSE OF LORDS SELECT  
COMMITTEE ON SCIENCE AND  
TECHNOLOGY REPORT:  
RESISTANCE TO ANTIBIOTICS**

*Presented to Parliament by the Secretary of State for Health  
By Command of Her Majesty  
July 2001*



WILLIAMS  
LIBRARY  
General Collections  
P  
6103



22501876002



WELLCOME LIBRARY  
INFORMATION SERVICE


16 AUG 2001

PCA Hea

DEPARTMENT OF HEALTH

**GOVERNMENT RESPONSE  
TO THE HOUSE OF LORDS SELECT  
COMMITTEE ON SCIENCE AND  
TECHNOLOGY REPORT:  
RESISTANCE TO ANTIBIOTICS**

*Presented to Parliament by the Secretary of State for Health  
By Command of Her Majesty  
July 2001*



DEPARTMENT OF HEALTH

GOVERNMENT RESPONSE  
TO THE HOUSE OF LORDS SELECT  
COMMITTEE REPORT

© Crown Copyright 2001

The text in this document may be reproduced free of charge in any format or media without requiring specific permission. This is subject to the material not being used in a derogatory manner or in a misleading context. The source of the material must be acknowledged as Crown copyright and the title of the document must be included when being reproduced as part of another publication or service.

Any enquiries relating to the copyright in this document should be addressed to HMSO, The Copyright Unit, St. Clements House, 2-16 Colegate, Norwich NR3 1BQ. Fax: 01603-723000 or e-mail: [copyright@hmso.gov.uk](mailto:copyright@hmso.gov.uk).

Printed in England by the Stationery Office  
© Crown Copyright 2001



# GOVERNMENT RESPONSE TO THE HOUSE OF LORDS SELECT COMMITTEE ON SCIENCE AND TECHNOLOGY REPORT: RESISTANCE TO ANTIBIOTICS

## Introduction

1. The Government very much welcomes the Committee's renewed consideration of the important issues surrounding the control of antimicrobial resistance. The Government fully recognises the seriousness of this problem and the need for sustained action. The Committee has undertaken invaluable work in highlighting the importance of the issue.

2. National and international interest in this subject remains high and the Government has done much to ensure that the UK is playing a leading role in tackling what it sees as a major public health threat. Indeed, at the European Union's recent follow-up conference 'The Microbial Threat: Progress Report on Antimicrobial Resistance', hosted by the Swedish Presidency, there was considerable interest in several aspects of the UK's strategy which were seen as innovative and developing approaches which others could build on. This particularly applied to the public education campaign, and the production of 'non-prescription' forms for use during primary care consultations, both aimed at reducing unnecessary prescribing of antimicrobials. That Governments should co-ordinate their actions across disciplines and between Government Departments and Agencies through a mechanism such as that achieved in the UK with the UK Interdepartmental Steering Group on Antimicrobial Resistance, was a key recommendation of this meeting.

3. As the Government has said before, however, there is no room at all for complacency about antimicrobial resistance and more still needs to be done. The Government was already aware of some of the weaknesses highlighted in the Committee's report and is taking steps to address them. The Government is also aware of the need for its strategy to evolve with time and to be the basis for long-term action.

4. Antimicrobial resistance cannot be considered in isolation. One important area of overlap is that of healthcare-associated infection. The Government is pressing ahead with arrangements for improved surveillance of both antimicrobial resistance and healthcare-associated infection, to establish more robust national information on the size of these problems and to track the progress of interventions. To support action in both these areas, the Government also recognises the need to gain a better knowledge of the extent to which antimicrobial agents are prescribed, particularly in hospitals, and this will be done. Work to obtain hospital antimicrobial prescribing data from a commercial source is continuing; in the longer term the information will be readily available with the introduction of the electronic patient record (EPR level 3)

5. There are many other areas where lack of information hampers policy development. The Department, working with others, has now identified an extensive programme of research needs and a call for research has recently been published.



6. The Government is pleased to report that the proposed new Specialist Advisory Committee has now been established to provide ongoing advice on the scientific aspects of this subject. The Advisory Committee's advice will enable the Government to review, and where necessary revise, the UK Antimicrobial Resistance Strategy and Action Plan to ensure that the wide ranging programme of work to tackle antimicrobial resistance is suitably built on and maintains its momentum.

7. The Government's response to the specific points and recommendations in the Committee's report follows.

### **The Government's strategy**

**The inevitable rise and spread of resistance will render existing drugs progressively less useful. In the absence of new drugs, this leaves us increasingly at the mercy of infections. We cannot eliminate resistance. We can however slow it down, by using antibiotics only when necessary, and by rigorous infection control and basic hygiene, both informed by thorough surveillance (para 3).**

8. The Committee's recommendation highlights the three main limbs of the UK's Antimicrobial Resistance Strategy, namely prudent use of antimicrobials and infection control, underpinned by surveillance. The Government notes the Committee's observation that it "*welcomes the effort that is being made, but [bureaucratic instruments; strategies, guidelines, circulars and the like] are no substitute for action on the ground. We caution against central guidance becoming too detailed and prescriptive*" (para 4). The Government agrees, and recognises the need for local ownership of the problem as a key to action at local and individual level. However, there needs to be an element of central oversight to ensure that action is being taken. The Interdepartmental Steering Group will continue to carry out this overseeing role.

9. The further responses below give more detail on elements of the strategy addressed by the Committee.

### **Prescribing by GP's**

**The significant fall in prescribing of antibiotics by GPs is a very welcome development (para 6). The "non-prescription pad" produced by the Department of Health in 1999 should be evaluated (para 7).**

10. A recent paper comparing non-hospital antibiotic sales across the EU showed the UK to have the 6th lowest sales (expressed as defined daily dose).<sup>1</sup> It has been gratifying to note the continued decline in prescriptions. A number of factors have almost certainly contributed to the reduction in antibiotic prescribing by GPs, including increased awareness among both health professionals and the public that antibiotics are not required for many common infections, and should be used with care. The 'non-prescription' pad was not evaluated on its own, but has been seen as an innovative feature of the public education campaign that could be repeated elsewhere.

11. The Government is keen to build on the reduction in antimicrobial prescribing already achieved in primary care, and to see it repeated in hospitals. A second phase of the public education campaign is currently being planned to

<sup>1</sup>Ref: Variations in antibiotic use in the European Union. Cars O, Molstad S, Melander A. Lancet 2001; 357: 1851-53.



include further publicity material and a resource pack for use in schools. The Department of Health has set up a Working Group to oversee the development of this material and, following evaluation of the pad, it will consider whether or not a revised version of the 'non-prescription pad' should be launched. Overall evaluation will be an integral part of the campaign.

### **Prescribing in hospitals**

**We encourage the Department to pursue as a matter of urgency hospital trusts which do not yet have a formal prescribing policy (para 9).**

12. A survey conducted by the Department of Health towards the end of last year provided a progress report on the action plans contained in health circulars HSC 1999/049 "Resistance to Antibiotics and other Antimicrobial Agents" and HSC 2000/02 "The management and control of hospital infection". The survey reported that antimicrobial prescribing policies were in place in 77% of Trusts. The remainder are being targeted by Regional Directors of Public Health who are leading the work to address the problem of antimicrobial resistance in their Regions, working with Regional Epidemiologists, Regional Prescribing leads and the NHS. All Trusts will be expected to have such policies in place.

13. In addition, a Medicines Management Performance Framework has been developed to support the clinical and cost-effective use of medicines within NHS Trusts. As part of this framework, a self-assessment tool has been developed by the Office of the Chief Pharmacist, with the support of the Regional Directors of Performance Management, Regional Directors of Public Health and Regional Pharmaceutical Advisors. This self-assessment tool recognises that achieving excellence in medicines management is an organisation-wide issue which requires managers, prescribers and pharmacists to work together. The assessment includes questions relating to the implementation of antimicrobial policies consistent with HSC 1999/049 and British Society of Antimicrobial Chemotherapy guidance. All Trusts were required to complete and return their own assessment by the end of April 2001.

### **Antibiotics for animals**

**We urge the veterinary profession to continue to reinforce the message of prudent use of antibiotics, especially the fluoroquinolones (para 13).**

14. This recommendation is addressed to the veterinary profession which is well aware of codes of practice produced by the British Veterinary Association, the Responsible Use of Medicines in Agriculture Alliance and the National Office of Animal Health Ltd. These codes all place emphasis on the need to use fluoroquinolones sparingly and certainly not as the treatment of first choice. Usage of fluoroquinolones, measured by UK sales, has remained fairly constant at about 1 tonne of active ingredient annually since products were first authorised in the early 1990s. In addition, the Veterinary Products Committee is currently reviewing US evidence that the use of fluoroquinolones in the drinking water of poultry may have led to the build up of resistance in campylobacter. The US FDA is minded to ban such use and a public hearing involving the manufacturer is likely to take place soon.

**We welcome MAFF's research into improved husbandry as an alternative to use of growth promoters, and look forward to seeing it turned into practice (para 14).**



15. The Department of the Environment, Food and Rural Affairs (DEFRA) is funding several projects which are looking at the influence of antimicrobial usage, management strategies and positive health plans on the incidence of antimicrobial resistance in micro-organisms from different food-producing animals. Projects are also looking at the effects of withdrawal of antimicrobial treatments, notably growth promoters, on the persistence of resistance in organisms from animal populations. These projects were commissioned in 2000 and have different completion deadlines. DEFRA is committed to placing the results of all the projects into the public domain. Certain suppliers of poultry meat to retailers have already adjusted husbandry systems so that antimicrobial growth promoters are not used in their production.

### **Public Education**

**We strongly recommend that a specific campaign against inappropriate use of antibiotics be repeated at frequent and regular intervals (para# 18). We encourage the Department of Health to pursue the placing of suitable articles of public health education in popular women's magazines (para 17).**

16. The Department of Health was pleased to see the impact of its 1998 campaign acknowledged by reproduction of one of its campaign posters as the cover of the Committee's report. The Working Group referred to in paragraph 10 is currently developing the strategy for phase two of the publicity campaign, with a launch expected in the Autumn of this year. Various target audiences are being considered, including women with children and carers of young children. It is likely that women's magazines will be one route for conveying the key messages.

17. This phase will be fully evaluated and decisions on future phases made in the light of that evaluation. Part of the Government's Strategy for tackling antimicrobial resistance is to encourage realistic expectations for antimicrobial prescribing and to emphasise the public's roles in helping to reduce the problem.

### **Professional education**

**We encourage the Department of Health to press ahead with their initiatives to improve coverage of antibiotic resistance in professional education (para 20).**

18. The Department has stimulated a wide range of initiatives in professional education. Although not having direct responsibility for the content of undergraduate medical curricula, the Department will continue to seek opportunities to influence the appropriate bodies in the hope that teaching on antimicrobials and antimicrobial resistance will be an integral part of core teaching on the management of infection in the future.

19. In keeping with the trend towards self-directed learning also encouraged by the GMC, a small group set up by the British Society for Antimicrobial Chemotherapy is continuing, with the support of the Clinical Prescribing Subgroup of the Interdepartmental Steering Group, to scope the possible production of materials to be used in undergraduate education. If successful, these may later be expanded for use in postgraduate education and continuing professional development.

20. In recognition that junior doctors are responsible for much antimicrobial prescribing in hospitals, the national standards referred to in paragraph 25 below include a requirement that junior doctors and specialist registrars should receive training in antimicrobial prescribing as part of their continuing professional development.



21. In addition, a review of the Senior House Officer (SHO) grade is currently in progress. It is hoped that this work will lead to the introduction of formal curricula for SHO training but the review is also focussing on principles and operational processes. Work on curricula will be done in collaboration with the Royal Colleges at a later implementation stage. This phase may offer an opportunity for the Department to again raise the issues of antibiotic resistance.

22. Other professional education initiatives have included the production and dissemination of the template guidelines for the management of infection in primary care from the PHLS; the Department of Health commissioned guidelines on prevention of healthcare-associated infections referred to in paragraph 26; and the National Electronic Library for Health's developing compendium of clinical evidence-based guidelines. Government-sponsored meetings for public health professionals, such as the recent antimicrobial resistance surveillance seminar at the Royal Society of Medicine, have informed and raised awareness about this issue.

### **MRSA**

**We are pleased that nationwide monitoring of MRSA in hospitals is now to go ahead (para 24).**

23. The Government is determined to establish a strong evidence base for action to tackle healthcare-associated infection and to contain resistance to antimicrobial agents.

24. Last year, the Department of Health established a Healthcare-associated Infection Surveillance Steering Group (HAISSG) to provide strategic advice on the surveillance of healthcare acquired infection. The Group is chaired by a Trust Chief Executive and includes representatives of the key players working in the NHS. The Group has identified the minimum data required for surveillance of MRSA infections in acute hospital trusts. The data are being collected by all acute NHS Trusts in England from 1 April this year and will be published from April 2002. This minimum data set is very much the first stage in the development of a comprehensive surveillance specification for the NHS to collect data on alert organisms, alert conditions, infections occurring post discharge and untoward events

### **Infection control and basic hygiene**

**We warmly welcome the Government's initiatives on infection control and cleanliness in hospitals, and the Minister's declaration that infection control and basic hygiene are "core issues" for the NHS (para 26). We urge the Department, in composing its tool kit for trusts on staffing levels and skill mix, to emphasise to trusts the crucial importance of a sufficient and properly supported team of infection control nurses (para 27).**

25. The Government agrees that infection control, by reducing the need for antimicrobials and reducing the spread of resistant organisms, is a fundamental part of any strategy to control antimicrobial resistance. It has given high priority to this area of work. In recognition of the particular importance of healthcare-associated infection, it has taken a number of steps over the last eighteen months to tackle this problem. Not all such infection is avoidable. However, its impact can be reduced significantly by better application of existing knowledge and proper adherence to well-established infection control practices.



26. Effective infection control, and action to control and reduce antimicrobial resistance are core requirements in the NHS Plan implementation programme. NHS Trusts and Health Authorities have been required to put infection control and basic hygiene at the heart of good management and clinical practice, with appropriate resources. The Government has made it clear that the prime responsibility for delivering improvements rests with each NHS Trust and its Chief Executive for which an action plan programme was set out in HSC 2000/02.

27. New national standards on infection control were issued to the NHS in November 1999. Their implementation is being independently reviewed and monitored by both the Audit Commission and the Commission for Health Improvement.

28. In addition, new Department of Health commissioned guidelines for the prevention and control of healthcare-associated infection in hospitals were published as a supplement to the Journal of Hospital Infection in January this year. These guidelines contain general principles for preventing infections in hospitals, including hand hygiene, universal infection control precautions, disposal of needles and sharp instruments and hospital hygiene. Global recognition of their value and importance has been confirmed by their recent selection for publication by the International Federation of Infection Control for distribution to 67 countries.

29. From April 2001, all hospitals have been required to invest in meeting standards of cleanliness set out in their Cleanliness Action Plan and to routinely monitor patients' views on the cleanliness of hospitals. National Standards of cleanliness will form part of the Performance Assessment Framework and every hospital will be measured against these standards. £31 million was invested last year followed by £30 million this year.

30. Discussions are at an early stage on the development of a tool kit for staffing levels and skills mix. The national infection control standard referred to in paragraph 25 makes it clear that acute Trusts must have an infection control team, including infection control nurse(s), and that the team should be supported, as appropriate, by adequate secretarial, IT and audit staff.

### **Infection control in community settings**

**Four years is too long to wait for action in such an important area as infection control in community settings such as nursing homes. Action should be taken immediately to address these concerns (para 29).**

31. In 1997, Regional Directors of Public Health commissioned the Regional Services Division of the PHLS Communicable Diseases Surveillance Centre to conduct "A study of the communicable disease control function in England, 1997". This was followed in 1998/99 by a collaborative study with the National Audit Office on "Hospital Infection Control in Acute NHS Trusts". To complement these studies the Regional Directors of Public Health have commissioned a study of infection control arrangements in community settings. In this study the term community will include schools as well as nursing and residential care homes. The overall outcome will be to describe the pattern of provision, together with the development of indicative standards. The study will highlight areas of Community Infection Control that need strengthening. This study is due to report in the summer of 2002.



32. The Department of Health has commissioned guidelines for the prevention and control of healthcare-associated infections in primary and community care. These guidelines form part of the National Institute of Clinical Excellence work programme and are due to be completed in 2002.

33. Following on from the Select Committee's first report in 1998, DH has commissioned a review of the role and responsibilities of Community Infection Control Nurses, to inform the development of service delivery models and their educational requirements. This will be completed in 2002.

### **Public Health Laboratory Service**

**We welcome the news that the PHLS's core funding from the Department of Health is now on a firm footing, with guaranteed inflation increases, plus growth funding for agreed developments (para 31).**

34. The Department of Health continues to review PHLS's funding year by year and to set it at a level which takes account of the priorities for PHLS, for public health policy and for the NHS more generally.

### **Research**

**We welcome the Minister's assurance that, though Departmental research funds are not available for routine surveillance, they are available for research which includes an element of surveillance, and we encourage researchers in this field to take full advantage of it (para 32).**

35. The Government is pleased that the Committee recognises the importance of research in the field of antimicrobial resistance and confirms that elements of surveillance are among the areas highlighted in the recent call for research in a variety of media at the end of June. This research programme was developed by the Interdepartmental Steering Group on Antimicrobial Resistance and has been endorsed by the Chairman of the Specialist Advisory Committee on Antimicrobial Resistance.

### **Compatibility of IT**

**We are disappointed that the Department was unable to give us even a target date for full compatibility of NHS and PHLS data-collection systems (para 33).**

36. The Department and the PHLS are working together in a number of areas to ensure that data collection systems are compatible. It is intended that alignment of respective strategies will be in place by March 2002.

37. The Department's Information Policy Unit (IPU) is contributing to the development of the PHLS' Information Management and Technology Strategy and will be invited to contribute to the assessment of the full business case for this strategy when it is completed.

38. The PHLS is contributing to NHS information policy in a number of key developments, including information networks, population registers and clinical messaging. The key contacts in both organisations are consulting directly with each other in these, and other areas. Proactive interaction will ensure that we have ongoing functional compatibility, so that data can continue to flow smoothly between the NHS and the PHLS.



### **Expert Advisory Group**

We are astonished that it has taken so long to set up a single multi-disciplinary expert advisory committee with a remit to advise Government on all aspects of the use of antibiotics, but we are glad that it is happening at last (para 34). We welcome the assurance that the advisory committee will be resourced at a level appropriate to what it sets out to do; we look forward to its implementation (para 35).

39. Membership of the Specialist Advisory Committee on Antimicrobial Resistance is now finalised, and details are given in Annex A. The Committee meets for the first time on 26 July 2001 and will agree a forward workplan, for which appropriate resources will be made available.

### **Conclusion**

40. The Committee's Report has once again raised important issues concerning antimicrobial resistance. The Government is fully committed to taking these forward in the context of the UK Strategy as it develops. The establishment of the new Specialist Advisory Committee will ensure that these issues remain high on the Government's agenda.

## MEMBERSHIP

SPECIALIST ADVISORY COMMITTEE ON ANTIMICROBIAL  
RESISTANCE

## CHAIR

**Professor Richard Wise** MB ChB MD FRCPath FRCP (Hon)  
Professor, Clinical Microbiology, City Hospital, Birmingham.

## MEMBERS

**Professor Anthony Hart** MBBS BSc PhD FRCPC FRCPath  
Head, Department of Medical Microbiology and Genitourinary Medicine,  
University of Liverpool

**Dr Anthony Howard** MB BS MSc FRCPath  
Director, Public Health Laboratory Service in Wales, Cardiff

**Dr David Livermore** BSc PhD  
Director, Antimicrobial Resistance Monitoring & Reference Laboratory,  
Public Health Laboratory Service, London

**Professor Alfred Emmerson** OBE FRCP FRCPath F MedSci  
Head of Clinical Microbiology, University of Nottingham

**Professor Roger Finch** FRCP FRCPath FFPM  
Professor, Infectious Diseases, University of Nottingham

**Dr Deenan Pillay** BSc MBBS PhD FRCPath  
Director, Public Health Laboratory Service Antiviral Susceptibility Reference  
Unit, University of Birmingham Medical School

**Professor Anne Johnson** BA MBBS MA MRCGP MSc MFCM MD  
FFPHM MRCP(Hon)  
Director, Centre for Infectious Disease Epidemiology, Royal Free and  
University College Medical School, London

**Dr Jonathan Nguyen-van-Tam** MBE BmedSci BM SB MFPHM  
Head of Medical Affairs (Specialty Products), Roche Products Ltd, Welwyn  
Garden City

**Dr Douglas Fleming** OBE MB ChB FRCGP PhD FMed Sci  
Director, Birmingham Research Unit, Royal College of General Practitioners

**Professor Quintin McKellar** BVMS PhD MRCVS  
Director, Moredun Research Institute

**Lord Soulsby of Swaffham Prior** MA PhD DSc DSc(Hon) DVM(Hon)  
DVM&S(Hon) DVMS(Hon) DVSM FRCVS AM(Hon)  
Past President, Royal Society of Medicine, Emeritus Professor of Animal  
Pathology, University of Cambridge

**Professor Alexander MacKenzie Johnston** BVM&S DvetMed FRCVS FRSH  
Professor of Veterinary Public Health and Head of Farm and Public Health  
Division, Royal Veterinary College, University of London

**Dr Michael Sharland** BSc (Physiol) MBBS MRCP (Paed) MD DTM+H  
FRCPC  
Chairman British Paediatric, Allergy and Immunology and Infection Group  
Consultant in Paediatric Infectious Diseases/HIV, St George's Hospital,  
London



**Dr Martin Wood** BMBCh MA FRCP

Consultant, Department of Infection & Tropical Medicine, Birmingham Heartlands Hospital. President, British Society for Antimicrobial Chemotherapy

**Dr Jonathan Cooke** MPharm PhD MRPS

Director of Pharmacy, Deputy Director Research and Development, Withington Hospital, Manchester

**Dr Mark Woodhead** BSc MBBS DM FRCP

Consultant Physician, Manchester Royal Infirmary

**Professor Peter Davey** MBBS MRCP MD FRCP

Professor of Pharmacoeconomics University of Dundee, Honorary Consultant in Infectious Diseases, Tayside University Hospitals Trust

**Mrs Susan MacQueen** MSc RGN RSCN ICN

Department of Microbiology and Infection Control, Great Ormond Street Hospital.

**Professor Crispian Scully** CBE BDS BSc MBBS PhD MD MDS LDSRCS

MRCs LRCP FDSRCS FFDRCS FDSRCS FRCPATH FDSRCS FMedSci

Director, Eastman Dental Institute, London

**Professor Tom Hayes** MB ChB FRCP,

Director & Dean, Postgraduate Studies, University of Wales College of Medicine, Cardiff

#### **LAY MEMBER**

**Mr Alan Wright** BA (Hons) LLB MA LLM TEFL

Communications/Legal Consultant – EQUUS (Training, Marketing & Communications)

#### **EX OFFICIO MEMBERS**

Director of the Public Health Laboratory Service (PHLS)

(**Dr Diana Walford** BSc MSc MD FRCP FRCPATH FFPHM)

Director of the PHLS Communicable Disease Surveillance Centre

(**Dr Angus Nicol** MA FRCP FFPHM MSc FRPCH)

#### **4 VACANCIES TO BE FILLED – ACTION BEING TAKEN**





**the  
Stationery  
Office**

**Published by The Stationery Office Limited**

and available from:

**The Stationery Office**

(Mail, telephone and fax orders only)

PO Box 29, Norwich NR3 1GN

General enquiries 0870 600 5522

Order through the Parliamentary Hotline *Lo-call* 0845 7 023474

Fax orders 0870 600 5533

Email [book.orders@theso.co.uk](mailto:book.orders@theso.co.uk)

Internet <http://www.clicktso.com>

**The Stationery Office Bookshops**

123 Kingsway, London WC2B 6PQ

020 7242 6393 Fax 020 7242 6394

68-69 Bull Street, Birmingham B4 6AD

0121 236 9696 Fax 0121 236 9699

33 Wine Street, Bristol BS1 2BQ

0117 9264306 Fax 0117 9294515

9-21 Princess Street, Manchester M60 8AS

0161 834 7201 Fax 0161 833 0634

16 Arthur Street, Belfast BT1 4GD

028 9023 8451 Fax 028 9023 5401

The Stationery Office Oriel Bookshop

18-19 High Street, Cardiff CF1 2BZ

029 2039 5548 Fax 029 2038 4347

71 Lothian Road, Edinburgh EH3 9AZ

0870 606 5566 Fax 0870 606 5588

**Accredited Agents**

(See Yellow Pages)

and through good booksellers

ISBN 0-10-152452-8



9 780101 524520